Show simple item record

dc.contributor.authorFelip, E.
dc.contributor.authorMajem, M.
dc.contributor.authorDoger, B.
dc.contributor.authorClay, T. D.
dc.contributor.authorCarcereny, E.
dc.contributor.authorBondarenko, I.
dc.contributor.authorPeguero, J. A.
dc.contributor.authorCobo-Dols, M.
dc.contributor.authorForster, M.
dc.contributor.authorUrsol, G.
dc.contributor.authorLedo, G. G.
dc.contributor.authorVila, L.
dc.contributor.authorKrebs, Matthew G
dc.contributor.authorIams, W. T.
dc.contributor.authorMueller, C.
dc.contributor.authorTriebel, F.
dc.date.accessioned2022-11-30T10:21:29Z
dc.date.available2022-11-30T10:21:29Z
dc.date.issued2022en
dc.identifier.citationFelip E, Majem M, Doger B, Clay TD, Carcereny E, Bondarenko I, et al. A phase II study (TACTI-002) in first-line metastatic non-small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected population. Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680302194.en
dc.identifier.doi10.1200/JCO.2022.40.16_suppl.9003en
dc.identifier.urihttp://hdl.handle.net/10541/625818
dc.language.isoenen
dc.relation.urlhttps://dx.doi.org/10.1200/JCO.2022.40.16_suppl.9003en
dc.titleA phase II study (TACTI-002) in first-line metastatic non-small cell lung carcinoma investigating eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab: Updated results from a PD-L1 unselected populationen
dc.typeMeetings and Proceedingsen
dc.contributor.departmentVall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain;en
dc.identifier.journalJournal of Clinical Oncologyen
dc.description.noteen]


This item appears in the following Collection(s)

Show simple item record